Floatz logo

ct-95

Mesothelin-positive Advanced Malignant Solid Tumors

Context Therapeutics Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Mesothelin-positive Advanced Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Anti-Mesothelin Car-T Cells
Zhejiang University
Phase 1CC
Uclm802 Cell
Zhejiang University
Phase 1CC
Fludarabine
Zhejiang University
N/AD
Cyclophosphamide
Zhejiang University
N/AD

Same molecule, other indications

ct-95 is also rated in:

neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
malignant pleural mesotheliomaDormant
CC
Indicative ·
43 / 100
View asset →
malignant peritoneal mesotheliomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →